- Topical minocycline gel 1% and 3% showed clinical benefit and good safety in a phase 2b trial of patients with papulopustular rosacea.
Why this matters
- Oral minocycline has previously shown efficacy for papulopustular, but a topical may have fewer systemic adverse effects.
- Minocycline was associated with decreased inflammatory lesions compared with vehicle:
- 1% minocycline, P=.0147.
- 3% minocycline, P=.0073.
- Minocycline 3% was associated with a higher rate of success by Investigator Global Assessment (P=.0379) and reduced erythema severity score (P=.0390) compared with vehicle.
- There were 3 treatment-related adverse events in the 1% minocycline group, 5 in the 3% minocycline group, and 1 in the vehicle group.
- 270 patients with papulopustular rosacea and 12-40 inflammatory lesions were randomly allocated to receive minocycline 1% (n=92), minocycline 3% (n=96), or vehicle (n=82) for 12 weeks.
- Data were analyzed for efficacy and safety outcomes.
- Funding: Hovione Sciencia Ltd.
- Few endpoints analyzed.
- Short study duration.
- Limited safety analysis.